Revenue doubled to USD 43.3m in 2025 with improved biological performance and premium pricing, but net loss widened to USD 191.2m due to a USD 115.3m impairment. Additional capital is needed in 2026, with material uncertainty regarding going concern.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.